Concepedia

Kami J. Maddocks

KJ

Statistics

Publications

116

Citations

8.6K

H-Index

43

Active since

2003

Affiliations

The Ohio State University(Current)

The University of Texas MD Anderson Cancer Center

The Ohio State University Wexner Medical Center

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Cornell University

Kami J. Maddocks is an author at The Ohio State University specializing in medicine, oncology, and immunology.

ORCID

Top concepts

Publications per year

2003–2024

116

Publications

116

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Jason A. Dubovsky, Kyle A. Beckwith, Gayathri Natarajan et al. · Blood · 2013 · 783 citations · Full text

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

Kami J. Maddocks, Amy S. Ruppert, Gerard Lozanski et al. · JAMA Oncology · 2015 · 568 citations · Full text

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

Gilles Salles, Johannes Duell, Eva González‐Barca et al. · The Lancet Oncology · 2020 · 504 citations · Full text

, , +5

<i>BTK</i><sup>C481S</sup>-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

Jennifer A. Woyach, Amy S. Ruppert, Daphne Guinn et al. · Journal of Clinical Oncology · 2017 · 461 citations · Full text

, , +14

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

Joseph A. Fraietta, Kyle A. Beckwith, Prachi Patel et al. · Blood · 2016 · 450 citations · Full text

Rows per page

1–5 of 116